Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05554653
Other study ID # ULE
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date October 1, 2022
Est. completion date August 2024

Study information

Verified date November 2023
Source University of Toronto
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective will be to determine the effect of leucine-enriched essential amino acids (LEAA) compared to carbohydrate placebo on dietary incorporation of [D5] Phenylalanine & [D5] Glycine into the three skeletal muscle protein pools (myofibrillar, sarcoplasmic and collagen), both following resistance exercise and at rest, with the two tracers provided as a 'intrinsically labeled' bolus. Other outcomes will relate to molecular regulation of protein synthesis.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 8
Est. completion date August 2024
Est. primary completion date October 3, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 35 Years
Eligibility Inclusion Criteria: - Healthy, male and female, recreationally-active participants. - Healthy will be defined as screened by the PAR-Q+ (The Physical Activity Readiness Questionnaire for everyone; Appendix B). - Self-reported not having engaged in resistance exercise and/or lower body plyometrics for at least 3 months prior to the study. - Participants will be aged 18-35 years old. - Participants are willing to abide by the compliance rules of this study. - Self-reported regular menstrual cycle (25-35d) within the last 3 months (female participants). Exclusion Criteria: - Inability to adhere to any of the compliance rules judged by principle investigator or medical doctor. - Self-reported regular tobacco use. - Self-reported illicit drug use (e.g. growth hormone, testosterone, etc.). - Individuals who have participated in studies within the past year involving any of the stable isotopes in the study. - Use of birth control and discontinued use within the last 3 months (female participants).

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Leucine enriched amino acids
Leucine enriched essential amino acids (4g total, of which 1.6g are leucine). 20g carbohydrate, 2g of protein free drink powder, and 5g of Splenda.
Carbohydrate Placebo
iso-caloric placebo (4g maltodextrin). 20g carbohydrate, 2g of protein free drink powder, and 5g of Splenda.

Locations

Country Name City State
Canada Goldring Centre for High Performance Sport at the University of Toronto Toronto Ontario

Sponsors (1)

Lead Sponsor Collaborator
Daniel Moore

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Other Isolation of primary myoblasts for in vitro nutritional experiments isolation of primary myoblasts from skeletal muscle biopsies for growth in vitro and nutritional experiments in cell culture models 6-9 months
Primary Myofibrillar Protein synthesis Rate of incorporation of orally ingested amino acid tracers (D5 Phe and D5 Gly) into myofibrillar proteins isolated from skeletal muscle biopsies 4h following drink (LEAA or PLA) consumption and resistance exercise or at rest. Enrichment will be quantified via tandem LC-MS/MS to derive a rate of incorporation over the 4h period. 4 hours
Secondary Sarcoplasmic protein synthesis Rate of incorporation of orally ingested amino acid tracers (D5 Phe and D5 Gly) into sarcoplasmic (i.e., soluble) proteins isolated from skeletal muscle biopsies 4h following drink consumption (LEAA or PLA) and resistance exercise or at rest. Enrichment will be quantified via tandem LC-MS/MS. 4 hours
Secondary Collagen protein synthesis Rate of incorporation of orally ingested amino acid tracers (D5 Phe and D5 Gly) into collagen (i.e., non-soluble) proteins isolated from skeletal muscle biopsies 4h following drink consumption (LEAA or PLA) and resistance exercise or at rest. Enrichment will be quantified via tandem LC-MS/MS. 4 hours
Secondary Protein localization via immunofluorescence Antibody-determined Phosphorylated RPS6 (S240/244) and mTOR protein localization in human muscle cross sections and longitudinal sections as examined via immunofluorescence. Muscle sections (both longitudinal and cross-sections) will be derived from snap-frozen muscle biopsies performed 4h following drink consumption (LEAA or PLA) with or without resistance exercise (unilateral). Localization will be performed as done by Hodson et al., (2022; AJP Cell). Particularly, the localization of these targets relative to the cell periphery and z-discs (longitudinal sections only) will be analyzed via colocalization analysis. 4 hours
See also
  Status Clinical Trial Phase
Completed NCT05336708 - The Effect of Acupressure on Fatigue N/A
Recruiting NCT06054620 - The Effect of Exercise and Presleep Nutrition on Muscle Connective Tissue Remodelling N/A
Recruiting NCT05060484 - A Phase II Study of SCT1000 in Healthy Women Aged 18 to 45 Years Phase 2
Completed NCT03756935 - Early Detection of Intra Operative Hypotension (IOH) During the Induction of General Anaesthesia
Recruiting NCT05145712 - Quantitative Bowel Readiness Assessment System in Predicting the Missed Detection Rate of Adenomas N/A
Completed NCT03853226 - Rational for the Use of Velocity-Pressure Loop in the Operating Room
Recruiting NCT03921164 - Non Invasive Use of Pressure-Volume Loop in the Operating Room
Completed NCT03876379 - Brain Power Spectral Density Under Propofol
Active, not recruiting NCT05754125 - In Vivo and in Vitro Anabolic Potential of Essential Amino Acids Following Resistance Exercise N/A
Recruiting NCT02778724 - France PCI Registry : National Observatory of Interventional Cardiology
Terminated NCT03585855 - Mesenchymal Stem Cell Transplantation in the Treatment of Chronic Antibody Mediated Kidney Graft Rejection (ABMR) N/A
Completed NCT03769142 - Cerebral Perfusion During Induction of General Anesthesia